Journal updates

We are excited to announce that Cancer Immunology, Immunotherapy has now become a fully open-access (OA) journal as of January 2024. This means that we will only be publishing articles as Open Access meaning content will be freely available to readers worldwide, enabling the widest possible dissemination and reuse.

Sign up for free online attendance.

Discover the range of academic oncology titles at Springer Nature here.

The journal is pleased to announce Dr. Haidong Dong has been named the new Editor-in-Chief of Cancer Immunology, Immunotherapy, effective January 1, 2020.